Carlsmed, Inc. Appoints Jennifer Kamocsay as Chief Legal Officer and Secretary
Carlsmed (Nasdaq: CARL), a medical technology company focused on AI-enabled personalized spine surgery solutions, has appointed Jennifer Kamocsay as Chief Legal Officer and Secretary. Kamocsay brings over 20 years of corporate legal experience from companies including Akoya Biosciences, Rubius Therapeutics, and Progress Software Corporation.
The appointment comes as Carlsmed strengthens its leadership team following its IPO and prepares for its cervical commercial launch. Kamocsay's experience spans corporate governance, securities law, and M&A initiatives, with previous roles at prestigious organizations including Skadden, Arps, Slate, Meagher & Flom LLP.
Carlsmed (Nasdaq: CARL), una società di tecnologia medica specializzata in soluzioni di chirurgia spinale personalizzata guidate dall'IA, ha nominato Jennifer Kamocsay come Chief Legal Officer e Segretaria. Kamocsay porta oltre 20 anni di esperienza legale aziendale da aziende tra cui Akoya Biosciences, Rubius Therapeutics e Progress Software Corporation.
L'incarico avviene mentre Carlsmed rafforza il proprio team dirigenziale dopo l'IPO e si prepara al lancio commerciale cervicale. L'esperienza di Kamocsay si estende dalla governance aziendale, al diritto societario sui titoli e alle iniziative di fusioni e acquisizioni, con ruoli precedenti in prestigiose organizzazioni tra cui Skadden, Arps, Slate, Meagher & Flom LLP.
Carlsmed (Nasdaq: CARL), una empresa de tecnología médica centrada en soluciones de cirugía de columna personalizadas potenciadas por IA, ha nombrado a Jennifer Kamocsay como Chief Legal Officer y Secretaria. Kamocsay aporta más de 20 años de experiencia legal corporativa de empresas como Akoya Biosciences, Rubius Therapeutics y Progress Software Corporation.
El nombramiento se produce mientras Carlsmed fortalece su equipo de liderazgo tras su IPO y se prepara para el lanzamiento comercial cervical. La experiencia de Kamocsay abarca gobernanza corporativa, derecho de valores y iniciativas de fusiones y adquisiciones, con roles anteriores en organizaciones de renombre como Skadden, Arps, Slate, Meagher & Flom LLP.
Carlsmed(Nasdaq: CARL), AI를 활용한 개인 맞춤 척추 수술 솔루션에 집중하는 의료기술 회사가 Jennifer Kamocsay를 최고법무책임자(CLO) 겸 비서로 임명했습니다. Kamocsay는 Akoya Biosciences, Rubius Therapeutics, Progress Software Corporation 등에서 20년이 넘는 기업 법무 경험을 보유하고 있습니다.
이번 임명은 IPO 이후 리더십 팀을 강화하고 경추 상용 출시를 준비하는 과정에서 이뤄졌습니다. Kamocsay의 경력은 기업 거버넌스, 증권법, M&A 이니셔티브를 포함하며 Skadden, Arps, Slate, Meagher & Flom LLP와 같은 권위 있는 조직에서의 이전 역할을 포함합니다.
Carlsmed (Bourse Nasdaq: CARL), une société de technologie médicale axée sur des solutions de chirurgie spinale personnalisée alimentées par l'IA, a nommé Jennifer Kamocsay au poste de Chief Legal Officer et Secrétaire. Kamocsay apporte plus de 20 ans d'expérience en droit des sociétés provenant d'entreprises telles que Akoya Biosciences, Rubius Therapeutics et Progress Software Corporation.
Cette nomination intervient alors que Carlsmed renforce son équipe de direction après son introduction en bourse et se prépare au lancement commercial cervical. L'expérience de Kamocsay couvre la gouvernance d'entreprise, le droit des valeurs mobilières et les initiatives de fusions et acquisitions, avec des rôles antérieurs dans des organisations prestigieuses telles que Skadden, Arps, Slate, Meagher & Flom LLP.
Carlsmed (Nasdaq: CARL), ein Medizintechnikunternehmen, das sich auf KI-gestützte personalisierte Wirbelsäulenchirurgie-Lösungen spezialisiert hat, hat Jennifer Kamocsay zur Chief Legal Officer und Sekretärin ernannt. Kamocsay bringt über 20 Jahre Erfahrung im Bereich Gesellschaftsrecht aus Unternehmen wie Akoya Biosciences, Rubius Therapeutics und Progress Software Corporation mit.
Die Besetzung erfolgt, während Carlsmed sein Führungsteam nach dem IPO stärkt und sich auf den zervikalen kommerziellen Markteintritt vorbereitet. Kamocsays Erfahrung erstreckt sich über Unternehmensführung, Wertpapierrecht und M&A-Initiativen, mit bisherigen Positionen bei renommierten Organisationen einschließlich Skadden, Arps, Slate, Meagher & Flom LLP.
Carlsmed (ناسداك: CARL)، وهي شركة تكنولوجيا طبية تركز على حلول جراحة العمود الفقري المخصّصة المعزَّزة بالذكاء الاصطناعي، عينت Jennifer Kamocsay كـالرئيسة القانونية وكـأمينة السر. Kamocsay لديها أكثر من 20 عاماً من الخبرة القانونية المؤسسية من شركات مثل Akoya Biosciences وRubius Therapeutics وProgress Software Corporation.
يأتي هذا التعيين بينما تعزز Carlsmed فريق القيادة بعد طرحها للاكتتاب العام وتستعد للإطلاق التجاري المتعلق بالمنطقة العنقية من العمود الفقري. وتتضمن خبرة Kamocsay الحوكمة المؤسسية، وقانون الأوراق المالية، ومبادرات الاندماج والاستحواذ، وشغلت مناصب سابقة في مؤسسات مرموقة مثل Skadden, Arps, Slate, Meagher & Flom LLP.
Carlsmed（纳斯达克股票代码：CARL），一家专注于AI驱动的个性化脊柱手术解决方案的医疗技术公司，已任命 Jennifer Kamocsay 为首席法务官兼秘书。Kamocsay 拥有来自 Akoya Biosciences、Rubius Therapeutics 和 Progress Software Corporation 等公司的超过 20 年的企业法务经验。
此任命发生在 Carlsmed IPO 后加强其领导团队、并为颈部区间的商业化推出做准备之际。Kamocsay 的经验覆盖公司治理、证券法和并购等领域，曾在知名机构 Skadden, Arps, Slate, Meagher & Flom LLP 任职。
- Strategic expansion of leadership team post-IPO with experienced legal counsel
- Addition of executive with over 20 years of relevant industry experience
- Strengthening of corporate governance ahead of cervical product launch
- None.
CARLSBAD, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced the appointment of Jenifer Kamocsay as Chief Legal Officer and Secretary, effective immediately. Ms. Kamocsay will serve as legal counsel for the Company and oversee compliance and corporate governance.
Ms. Kamocsay brings more than two decades of corporate legal experience as in-house counsel across life science and technology sectors at Akoya Biosicences, Rubius Therapeutics, Inc. and Progress Software Corporation.
“We are pleased to welcome Jennifer to the Carlsmed leadership team as we strengthen our organization and strategically expand our leadership team following our IPO,” said Mike Cordonnier, Chairman and CEO of Carlsmed. “Her deep expertise in corporate governance, securities law and broader legal strategy will be instrumental as we continue to scale our business and prepare for our cervical commercial launch.”
Prior to Akoya, Ms. Kamocsay served as General Counsel and Corporate Secretary of Rubius Therapeutics, Inc., where she was responsible for overseeing and managing all of the company’s legal affairs. Before Rubius, she served as Associate General Counsel and Assistant Secretary at Progress Software Corporation, where she managed the company’s corporate, securities law, and M&A initiatives. Ms. Kamocsay began her career at Skadden, Arps, Slate, Meagher & Flom LLP, where she provided counsel to public and private company clients in the biotechnology and pharmaceutical industries on M&A, securities law, and corporate governance matters. Ms. Kamocsay holds a B.A. in History from the University of California, Los Angeles and a J.D. from Northeastern University School of Law.
About Carlsmed, Inc.
Carlsmed is a medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond.
Forward Looking Statement
Any statements in this press release about future expectations, plans and prospects, including statements about the Carlsmed’s ability to scale the impact of its aprevo technology platform and advance its personalized spine surgery platform to transform patient outcomes and drive long-term growth, Carlsmed’s current expectation of launching aprevo cervical in the United States in 2026, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including such important factors as are set forth under the caption “Risk Factors” in the Carlsmed’s Registration Statement on Form S-1 on file with the U.S. Securities and Exchange Commission. The forward-looking statements included in this press release represent Carlsmed’s views as of the date of this press release. Carlsmed anticipates that subsequent events and developments will cause its views to change. However, while Carlsmed may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Carlsmed’s views as of any date subsequent to the date of this press release.
Investor Relations
Caroline Corner, PhD
IR@Carlsmed.com
Media
LeAnn Burton
Senior Director Brand Marketing
LBurton@Carlsmed.com
FAQ
Who is Jennifer Kamocsay and what is her new role at Carlsmed (CARL)?
What is Carlsmed's (CARL) business focus?
What are Carlsmed's (CARL) upcoming business initiatives?
What is Jennifer Kamocsay's professional background before joining Carlsmed (CARL)?
When does Jennifer Kamocsay start her role at Carlsmed (CARL)?
